Connecting Off-Label Marketing To Use: Not Quite A To B

Law360, New York (June 7, 2012, 1:01 PM EDT) -- In a recent decision of first impression in the U.S. Court of Appeals for the Third Circuit, the court in In re: Schering-Plough Corp. held that two groups of plaintiffs lacked standing to pursue claims against pharmaceutical manufacturer Schering-Plough Corp. and its affiliated marketing and sales companies for marketing drugs for off-label uses.

Affirming the district court's decision, the Third Circuit dismissed the claims because the complaints failed to adequately plead the required injury-in-fact causation element.

Schering-Plough manufactured certain oncology and hepatitis drugs and purportedly advertised...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.